![](https://cdn.statically.io/img/www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fcms-image-bucket-production-ap-northeast-1-a7d2.s3.ap-northeast-1.amazonaws.com%2Fimages%2F9%2F8%2F1%2F0%2F47330189-3-eng-GB%2FCropped-1708922785170890294341723.jpeg?width=700&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms)
After enduring the chill of a prolonged capital winter, China's drugmakers have begun to feel a thawing breeze.
Dealmaking has surged in 2024, with the nation's pharmaceutical industry attracting increased attention from international rivals for their innovative treatments. Last year, Chinese drugmakers set a record for new drug out-licensing deals -- in which a company allows another party to use its product, technology or intellectual property -- and saw the first-ever acquisition of a domestic biotech company by a multinational pharmaceutical giant.